- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.12. | Upstream Bio to be Added to Russell 2000 | - | Baystreet.ca | ||
| 16.12. | Upstream Bio to join Russell 2000 index | 2 | Seeking Alpha | ||
| 16.12. | Upstream Bio Announces Addition to Russell 2000 Index | 1 | GlobeNewswire (USA) | ||
| 07.11. | Upstream Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11. | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11. | Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say | 3 | Benzinga.com | ||
| 05.11. | TD Cowen bullish on Upstream Bio, bets on differentiated asthma treatment verekitug | 1 | Investing.com | ||
| UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
| 05.11. | Piper Sandler sees big potential for Upstream Bio asthma therapy, Overweight on stock | 2 | Investing.com | ||
| 05.11. | Piper Sandler sieht großes Potenzial für Upstream Bio's Asthma-Therapie, bewertet Aktie mit "Overweight" | 1 | Investing.com Deutsch | ||
| 05.11. | JPMorgan bullish on Upstream Bio stock, bets on promising asthma drug pipeline | 2 | Investing.com | ||
| 05.11. | JPMorgan optimistisch für Upstream Bio-Aktie, setzt auf vielversprechende Asthma-Medikamenten-Pipeline | 3 | Investing.com Deutsch | ||
| 18.10. | Upstream Bio, Inc. (NASDAQ:UPB) Director Buys $14,025,000.00 in Stock | 1 | MarketBeat | ||
| 15.10. | Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | 88 | GlobeNewswire (Europe) | WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on... ► Artikel lesen | |
| 15.10. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.10. | IPO Radar: Cerebras, Upstream Bio and Applied Nutrition | 13 | The Armchair Trader | ||
| 14.10. | Erfolgreicher Börsengang von Upstream Bio | 2 | investrends.ch | ||
| 14.10. | HBM Healthcare Investments AG: Erfolgreicher Börsengang des HBM-Portfoliounternehmens Upstream Bio; Kapitalaufnahme von USD 255 Millionen | 751 | EQS Group (DE) | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
Erfolgreicher Börsengang des HBM-Portfoliounternehmens Upstream Bio; Kapitalaufnahme von USD 255 Millionen
14.10.2024... ► Artikel lesen | |
| 11.10. | Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M | 1 | MedCity News | ||
| 11.10. | Upstream Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 11.10. | Upstream Bio stock rallies 32% following upsized $255M IPO | 1 | Seeking Alpha |
Seite:
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 7,270 | +0,41 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| TEMPUS AI | 34,650 | -0,40 % | Tempus AI (NASDAQ:TEM) Shares Down 5.7% Following Insider Selling | ||
| SUMMIT THERAPEUTICS | 18,940 | -0,32 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| ADMA BIOLOGICS | 17,390 | -0,11 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| EDGEWISE THERAPEUTICS | 29,660 | +0,14 % | Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains | ||
| 180 LIFE SCIENCES | 2,740 | -5,52 % | 180 Life Sciences Corp. - S-1/A, General form for registration of securities | ||
| JANUX THERAPEUTICS | 56,13 | -0,02 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 36,810 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 11,450 | +0,35 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Announces neffy (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies | ||
| ARCUTIS BIOTHERAPEUTICS | 14,980 | -0,07 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
| NUVALENT | 82,83 | +0,22 % | Nuvalent-CEO Porter James Richard verkauft Aktien im Wert von 2,34 Millionen US-Dollar | ||
| ARCELLX | 77,10 | -0,62 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| ALPHA TEKNOVA | 8,615 | +0,17 % | Alpha Teknova Stock Hits 52-Week High at $8.93 Amid Growth Surge | ||
| NEUMORA THERAPEUTICS | 10,745 | +1,08 % | Neumora Therapeutics (NASDAQ:NMRA) Shares Down 3% - Should You Sell? | ||
| HUMACYTE | 4,525 | +0,33 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen |
UPSTREAM BIO INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 19,370 Euro und damit -0,15 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu UPSTREAM BIO INC finden Sie auf Wallstreet Online.
